Liquid Biopsies

The FDA’s Molecular and Clinical Genetics advisory committee has unanimously supported the safety, efficacy, and positive risk-benefit profile of the noninvasive stool-based DNA test Cologuard in a 10-0 vote.

Screening for prostate-specific antigen (PSA) significantly cuts the death rate from prostate cancer, but at the same time, America’s medical community should work harder to avoid the screen’s potential pitfalls.

Although the use of CTCs as a “liquid biopsy” to detect tumor growth has long been a goal, developing the technology for detecting and analyzing CTCs has been a challenge.

A new study suggests that even tumor cells with a common genetic background can display functional heterogeneity.